非小细胞肺癌中Tiam-1的表达及其临床病理意义

Expression and clinicopathological significance of Tiam-1 in non-small cell lung cancer

目的:探讨T淋巴瘤侵袭和转移诱导蛋白(Tiam-1)在非小细胞肺癌(NSCLC)中的表达及临床意义。方法:应用免疫组化S-P法检测86例NSCLC病理标本的Tiam-1表达情况。结果:NSCLC中Tiam-1的表达阳性率为55.8%,与年龄、性别、组织学类型及分化程度间均无明显相关性(P>0.05)。Tima1阳性表达率与患者PTNM分期及淋巴结转移密切相关(P<0.05)。在获得术后随访的47例患者中,生存期<3年者19例,阳性表达15例,生存期≥3年者28例,阳性表达9例,两组间差异有统计学意义(P<0.01)。结论:Tiam-1过度表达与NSCLC的发展、淋巴结转移及预后有密切关系,有可能作为临床评估NSCLC进展及预测肿瘤转移潜能和预后的指标。

Objective： To investigate the expression and clinicopathological significance of T lymphoma invasion and metastasis factor 1 （Tiam-1） in non-small cell lung cancer （NSCLC）. Methods： Expression of Tiam-1 in lung cancer tissues was detected in 86 patients with lung cancer by using immunohistochemistry S-P method. Results： The positive rate of Tiam-1 expression in NSCLC was 55.8% , which was related to TNM stage, but not to cell differentiation, sex, and age of the patients （ P 〉 0.05）. The positive rate of Tiam-1 expression was 41.8% （23/55） in stage Ⅰ ＋Ⅱ and 80.6% （25/31 ） in stage Ⅲ ＋Ⅳ. A higldy significant difference existed between the 2 groups （ P 〈0, 01 ）. The positive rate of Tiam-1 expression was significantly higher in NSCLC with lymph node metastasis （78.4% , 29/37） than that without lymph node metastasis （38.8% , 19/49） （ P 〈0.01 ）. The 3-year sutrvival rate （84.2% , 15/19） in patients with low Tiam-1 expression was significantly higher than that （32.1% , 9/28） with high Tiam-1 expression （ P 〈0.05）. Conclusion：Overexpression of Tiam-1 may be involved in the progression and metastasis of the cancer and prognosis of the patients with lung cancer. It might be helpful to evaluate the progression of the cancer, and to predict the metastasis and progression of lung cancer.